Testing a new method for detecting certain bacteria in lung infections
Part of Infections, Lungs & breathing clinical trials.
This study checks if a special test (Xpert Carba-R) can find a type of drug-resistant bacteria, called CRE, in fluid from the lungs and in rectal swabs. It might help doctors treat lower respiratory tract infections more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a type of bacteria called CRKP in your lower respiratory tract (like sputum or BAL fluid) within the last 15 days.
- You have a lower respiratory tract infection shown by at least two of these: fever over 100.7°F or below 97.7°F, high or low white blood cell count (more than 10,000 or less than 4,000), or thick, yellowish mucus from your airways.
- You do not have other bacteria that can make certain antibiotics stop working in your lower respiratory tract.
- You have never had an infection with CRE before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a faster test to find CPE, a type of bacteria that is resistant to many antibiotics. If you test positive for CPE while in the hospital, your information may be used to help improve how we screen and manage this bacteria.
This trial tests a medicine called colistimethate sodium for people in the hospital with a serious infection (pneumonia or bloodstream infection) caused by a resistant bacteria called CRE. The goal is to see if this antibiotic can effectively treat the infection.
This trial tests a faster way to detect Pseudomonas aeruginosa, a common cause of lung infections, using special imaging. It aims to see if this rapid test can help doctors track how well treatment is working.
This study looks at whether a rapid test can help doctors detect CPE bacteria (which are resistant to many antibiotics) sooner, and whether using infection control measures can stop these bacteria from spreading. It may help you get the right care and reduce the risk of infection while in the hospital.
This study looks at patients who have severe infections caused by carbapenem-resistant Enterobacterales (CRE), which are bacteria that are hard to treat because they resist many antibiotics. It will examine the germs and how patients respond to newer antibiotics that are specifically used for these tough infections.
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
Hear when a new Carbapenem-Resistant Enterobacteriaceae trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.